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ABSTRACT (271 words/with required revisions = 301 ) 
Background: Breast cancer treatments often result in upper extremity functional limitations in the 
short and long term. Current evidence makes comparisons against a baseline or contralateral 
limb, but does not consider changes in function associated with aging.  
Objective:  To compare upper extremity function between women treated for breast cancer more 
than 12 months in the past and women without cancer.  
Design: Observational cross-sectional study. 
Methods:  Women diagnosed with breast cancer (BC) with a post-surgical treatment mean of 51 
months (range 12-336 months) were compared to women without breast cancer (CTRL). Self-
reported upper extremity function using the Disabilities of the Arm, Shoulder and Hand (DASH), 
and shoulder range of motion, strength, and muscular endurance were measured. Participants 
were divided into 3 groups: BC involved non-dominant (BC-ND), BC involved dominant (BC-
DOM), and CTRL. 
Results:  A total of 59 CTRL, 23 BC-ND, and 28 BC-DOM, completed measures. Mean BC 
DASH scores were higher than CTRL regardless of limb on which cancer occurred (p<.01, 
ES=1.13). BC-ND range of motion was significantly less for flexion (p=0.006, ES=1.19) and 
external rotation (p=0.009, ES=1.11) compared to CTRL. Strength of external and internal 
rotation for BC-ND was 23-25% lower than CTRL (p=0.003, 0.001, ES=0.89, 0.92 respectively). 
Endurance was not significantly different between three groups (p>0.05). 
Limitations:  Some participants had rehabilitation which may skew results.  Range of post-
surgical time was broad, making it difficult to determine when function returned.  Muscular 
endurance measures demonstrated a ceiling effect and large variance, limiting the ability to 
distinguish differences among participants. These results may not be generalizable to the 
 
subset of women who were treated with lumpectomy, sentinel node biopsy, or chest wall 
radiation alone. 
Conclusion: Long-term, women with BC have lower self-reported shoulder function than women 
without BC. Motion and strength are lower among women who have experienced cancer on the 
non-dominant limb.  
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(3232 words/ with required revisions = 3622) 
INTRODUCTION  
With the five-year survival rate of breast cancer at nearly 90%, currently over 3 million women 
are living after a diagnosis of breast cancer.1  Upper extremity functional deficits following 
surgical and radiation treatments persist beyond the first year.2-4 Declines of upper extremity 
function compared to a pre-cancer level are self-reported in 21-35% of women treated for 
breast cancer (BC) up to six years following diagnosis.5,6  The more involved the treatment, 
the greater risk of upper extremity morbidity.  In women surgically treated with 
mastectomy and axillary lymph node dissection (ALND), and who undergo axillary 
radiation, upper extremity deficits in function are reported at greater levels than with 
lumpectomy and/or sentinel node dissection surgeries.7  The extent of these reported deficits 
and whether they can be attributed to breast cancer surgery and treatment or to normal aging has 
not been examined adequately.  
Functional performance of the upper extremity includes adequate levels of arm motion, 
strength, and muscular endurance. Declines in motion are reported among women treated for 
breast cancer in the long term, with one study reporting >10% decline in flexion more than 5 
years following treatment for breast cancer,8 and another study identifying that losses of  ≥20° of 
motion were present 7 years after surgical treatment.9  Upper extremity strength declines of 10-
15% are reported 1-5 years after treatment for breast cancer.10  Muscular endurance, the ability 
to sustain an activity over time, has been minimally examined among BC but conflicting results 
from no deficits11 to a 20% deficit in muscular endurance are reported.12,13  To date, studies on 
upper extremity functional performance in BC have primarily used self-reported measures or 
measured changes relative to the contralateral limb, assuming this limb is without deficit and 
 
functions similarly. Direct comparisons to an age-matched group of women without breast 
cancer have not been reported for long-term women with BC.  Furthermore, range of motion 
(ROM) and strength among healthy women is dependent on limb dominance14,15 therefore 
involved limb dominance should be considered when making comparisons between these groups.  
Deficits in self-reported and objective measures of upper extremity function among long-
term BC may be in part a result of changes seen with normal aging. Direct comparisons of upper 
extremity function measured by self-report, ROM, strength, and muscular endurance between 
BC and healthy women are important to determine whether existing deficits are due to treatment 
or normal aging. The purpose of this study was to compare upper extremity function of long-
term BC to a population of women without breast cancer.  
METHODS 
Participants: A convenience sample of 59 healthy women (CTRL), 25 women with breast cancer 
on the non-dominant limb (BC-ND), and 29 women with breast cancer on the dominant limb 
(BC-DOM) recruited via word-of-mouth, flyers, and email agreed to participate. All 
participants were between 40 and 69 years. The CTRL group had no history of breast cancer, 
while the BC group underwent at least one of the following treatments a minimum of 12 months 
prior to participation:  mastectomy, axillary lymph node dissection, axillary radiation. 
Participants were excluded with any history of shoulder, cervical, or thoracic spine pathology 
diagnosed by a physician within the previous six months, or any history of shoulder, cervical, or 
thoracic surgery so as to not confound findings. One participant with breast cancer was 
excluded after screening revealed she had undergone rotator cuff surgery on her involved side 
prior to the cancer diagnosis. Two other BC were excluded after clarification that the radiation 
 
received was local to the tumor site and not the axilla. The final analyses included 23 BC-ND 
and 28 BC-DOM.  
Sample size was based a priori on a study examining self-reported function between 
women with and without breast cancer. Evaluating Disabilities of the Arm, Shoulder, and Hand 
(DASH) scores and flexion ROM measures between BC six months after treatment and healthy 
controls,16 an estimated 14-16 participants per group was required to meet a power of 90%. The 
study procedures were explained to all participants, and after questions were answered, each 
completed consent prior to data collection.  This study was approved by the Institutional Review 
Boards of the University of Kentucky, Lexington, Kentucky, the University of Dayton and 
Miami Valley Hospital, Dayton, Ohio.  
Procedures:   
On a single visit, each participant’s objective upper extremity function was measured by a 
battery of tests: bilateral shoulder ROM and strength in three planes, and muscular endurance 
using the Functional Impairment Test – Hand and Neck, Shoulder, Arm (FIT-HaNSA), by one of 
three trained investigators.17 Participants completed a demographic questionnaire, the 
International Physical Activity Questionnaire (IPAQ) and the DASH prior to completing other 
components of testing. Demographic variables of age and arm dominance were recorded, and 
height and weight were measured to determine body mass index.  
Patient-reported Measures: 
Activity level was measured by the 7-item IPAQ, which has good test-retest reliability 
(Spearman r = .70-.90).18  Self-reported upper extremity function was measured by the DASH, a 
30-item disability scale scored 0 to 100; lower scores denote less disability. Construct and 
 
convergent validity have been established with other shoulder functional scales, and the test-
retest reliability within BC is excellent (ICC=0.97).19-22  
Objective Clinical Measures: 
Range of Motion:  Bilateral active ROM of shoulder flexion, external rotation (ER), and 
hand behind back (HBB) were measured by taking photographs of the participant completing 
each motion. The HBB motion was chosen as a representation of a functional measure of internal 
rotation, often utilized clinically. Degrees of motion were calculated using ImageJ (National 
Institutes of Health, Washington DC) by the primary investigator. The ICC for intra-rater 
reliability of digital measurement of ROM was consistently >0.95, with a standard error of 
measurement <2°.  
Shoulder flexion and ER measurements were taken by placing markers along the axes of 
motion as described by Norkin and White;23 the marker for the HBB measure was placed at the 
level of the C7 spinous process.24,25  Shoulder flexion measurements were taken in standing; 
ER was taken with the participant’s upper arm supported on two towels while lying supine 
with the arm at 90° of abduction and 90° elbow flexion. Participants were instructed to 
complete the motion as far as possible, and a photograph was taken at this end range. This was 
repeated twice bilaterally with the mean of the two measures used for analysis.23 The shoulder 
flexion angle was the intersection of two lines, one representing the shoulder and the other the 
thorax (Figure 1a). The shoulder ER angle was formed by a line drawn through the shaft of the 
ulna and a line perpendicular to the plinth (Figure 1b). To measure the HBB distance, a 10cm 
reference was in the same plane as the participant to provide a spatial scale of the image for 
accurate measurement.26 The distance in centimeters from the C7 spinous process to the spinous 
process in line with the tip of the thumb was recorded (Figure 1c).24  A lower value indicates 
 
greater motion. Inter-rater reliability of the ROM procedures was established in pilot testing of 
eight healthy female adults prior to data collection (ICCs = 0.90-0.99).  
Strength:  The strength of the shoulder flexors, internal rotators, and external rotators was 
measured by hand-held dynamometry (Lafayette Manual Muscle Test System, Lafayette 
Instruments, Lafayette, IN) using standard testing positions.27 An inelastic 2” wide nylon strap 
was placed around the participant’s limb and the testers’ body for each motion to provide a 
consistent, immovable resistance for the hand-held dynamometer (Figure 2).28-30 Each participant 
was instructed to generate force to a maximal level over five seconds in each direction of 
testing.31,32 Two submaximal practice trials were completed prior to testing, followed by three 
trials with 10 seconds rest in between. The average strength in kilograms (kg) of the three trials 
was used for statistical analysis.33 Strength was normalized to body weight and is presented as a 
percentage of body weight (kg of force/body weight in kg). Shoulder flexion was measured with 
the participant seated, arm elevated to 90° (Figure 2a).27 To measure IR and ER, the participant’s 
upper arm was supported on two towels while lying supine with the arm at 90° of abduction and 
90°elbow flexion (Figures 2b, 2c).27  In pilot testing with eight participants, the ICCs for inter-
rater reliability for strength measures ranged from 0.78-0.80, and the standard error of 
measurement was consistently below 1.2% of body weight.  
Muscular Endurance: Upper extremity muscular endurance was measured by the FIT-
HaNSA sub-tests 2 and 3 following a previously established protocol for performance and 
termination of testing.17 The FIT-HaNSA challenges muscular endurance by completing a series 
of repetitive tasks involving lifting 1kg from eye level down 25 cm, and a sustained manipulation 
task with nuts and bolts above the head (Figures 3a, 3b). The FIT-HaNSA demonstrates good-
 
excellent test-retest reliability (ICC=0.79-0.97), and moderate concurrent validity (r=0.71-0.76) 
with self-reported upper extremity functional scales (Figures 3 and 4).17,27   
Statistical Analysis 
BC were divided into groups based on which side the cancer occurred:  dominant (BC-
DOM) or non-dominant (BC-ND).  For comparison analyses, the same limb was used for both 
the CTRL and BC groups: BC-DOM was compared to the dominant limb of the CTRL group, 
whereas BC-ND was compared to the non-dominant limb of CTRL.  For analyses which did not 
depend on laterality, the full BC group was compared to the CTRL group. 
Descriptive statistics were calculated for all variables. Data were examined for 
assumptions of normality using Kolmogorov-Smirnov test. All data were normally distributed (p 
<0.05) except for the DASH and FIT-HaNSA scores. Since the sample size is robust and the 
variance small, the DASH and FIT-HaNSA were evaluated with parametric tests, 
consistent with other literature in this area.5,17 Participant demographics of age, body mass 
index, activity level, and DASH scores were compared using a one-way analysis of variance 
(ANOVA). Separate multivariate analyses of variance (MANOVA) were used to analyze all 
ROM, strength and muscular endurance measures. Where significance was found on the 
ANOVA and MANOVA, Games-Howell post hoc testing determined the direction of 
significance based on unequal group sizes with unequal variances.34 Significance was established 
a priori at p≤.05. All data were analyzed using IBM SPSS Statistics 23 (Armonk, NY).  
RESULTS 
The ANOVA revealed no significant differences in potential confounders of age 
(p=0.23), body mass index (p=0.59) and activity levels (p=0.78) between the three groups. 
Among BC, the median duration since surgical treatment was 51 months (range 12-336); 34 
 
(66.7%) underwent a mastectomy, 22 (43.1%) underwent ALND, and 14 (27.4%) had axillary 
radiation. Of these, 23 (45.1%) underwent a mastectomy alone, 5 (9.8%) had both a mastectomy 
and ALND, 6 (11.8%) underwent an ALND and axillary radiation, and 6 (11.8%) underwent all 
three procedures. Of the 34 women who underwent a mastectomy, data on reconstruction 
status were available from 26 (76.4%), with 11 (42.3%) women not having reconstructive 
surgery, 12 (46.2%) having implant reconstruction, 2 (7.7%) having TRAM flap 
reconstruction, and 1 (3.4%) having latissimus reconstruction. More than half of the 
participants (68.6%) who answered the question about prior therapy intervention for their 
shoulder did not have previous treatment. Of those who received therapy, the majority 
received lymphedema treatment and education, with a small portion receiving exercise to 
improve motion.  Enrolled participants came from a broad geographic area including 5 
counties encompassing urban, suburban, and rural locales. Participant demographics are 
detailed in Table 1.  
The ANOVA for the DASH resulted in statistically significantly differences between 
both BC groups and controls. Tukey post hoc testing revealed significance between BC-
DOM and CTRL (p≤0.001), and for BC-ND and CTRL (p=0.008) (Table 2). The MANOVA 
for ROM measures revealed statistically significant differences between BC-ND and CTRL 
(p≤0.001). Games-Howell post hoc testing indicated that BC-ND had statistically significantly 
less flexion (p=0.006) and ER (p=0.009) motion than CTRL (Table 2). Strength was 
significantly less among BC-ND for shoulder internal (p≤0.001) and external rotation (p=0.003) 
than for the CTRL (Table 2).  FIT-HaNSA testing resulted in no statistically significant 
differences between groups (p>0.05). 
 
DISCUSSION 
This unique study directly compared DASH scores and shoulder ROM, strength, and 
muscular endurance between BC and healthy controls, while considering involved limb 
dominance. These comparisons have not been investigated among long-term BC. The results 
suggest that persistent deficits may be a result of breast cancer treatment and are not due to 
aging. Women treated for breast cancer report higher DASH scores (disability) regardless of 
which limb is involved. Those with cancer affecting their non-dominant limb demonstrate less 
upper extremity ROM and strength than a control sample of women without breast cancer. Based 
on these findings, clinical interventions may need to be different based on the side affected by 
breast cancer. 
DASH scores were statistically significantly higher among BC compared to levels 
reported by this healthy sample, implying lower levels of overall upper extremity function. 
Caution should be exercised however, as this level of perceived function may not be clinically 
relevant when compared to DASH values among a larger population. The mean DASH score of a 
general population sample of 1706 adults was 10.1±14.7,35 and among 327 women ages 18-65, 
the mean DASH score was 14.3±14.9.36 That the control population in this study reported DASH 
scores much lower than the general population is likely due to study criteria for participation that 
included no current shoulder dysfunction. In comparing our results (mean score 12.0-12.3) to a 
general population, our sample of BC that were on average four years post-treatment reported 
similar levels of function. These findings indicate that BC can expect recovery of function 
similar to the population as a whole with adequate time. Yet months to years after treatment, 
over 20% of women treated for breast cancer score greater than 20 on the DASH.5 Given 
the large effect sizes of the results, the findings in this study may suggest that the diagnosis 
 
of cancer can overlay the reality of recovery and that women treated for breast cancer continue 
to perceive that recovery is incomplete. The self-reported function of the breast cancer groups 
remains lower than our control population without shoulder impairment.  
Nearly all ROM measures in BC were impaired by 4-12% compared to a healthy sample 
even four years after treatment. Only the HBB measure was not significantly diminished, yet 
when comparing raw numbers, the women with breast cancer on the dominate side demonstrated 
3.5% less motion than the control group, while those with cancer on the non-dominant side 
demonstrated a 23% less motion. This greater loss on the non-dominant side suggests greater 
impact of the cancer experience on this side. The mean shoulder flexion motion among BC in 
this study is 12-17° less than that reported among BC within the first six months after 
treatment,16 suggesting that shoulder flexion ROM loss may continue past one year. Although 
none of the averages of motion are below what is generally accepted as clinically significant 
level, a minimum range of 148° of shoulder flexion is documented as necessary for reaching a 
high shelf.37  A secondary analysis of BC with motion less than 148° revealed that 30 of 52 
(58%) BC participants did not have this level of motion available on the involved limb. The ER 
motion, although statistically significantly less among BC-ND, is not considered to be clinically 
deficient at 83° as most functional tasks can be completed with this available range.  While 
women with breast cancer four years following treatment generally demonstrate ROM at an 
adequate level to complete most daily activities, these women may have difficulty completing 
tasks requiring what is generally accepted as full range of motion such as reaching to higher 
heights or participating in overhead activities.  Furthermore, the effect sizes of these results 
(>1) suggest that the differences seen are greater than one standard deviation from the 
 
mean.  It is important to understand that even four years after treatment, these women 
demonstrate motion at levels less than their peers without breast cancer. 
Strength differences compared to the control group were found to affect primarily BC 
who had cancer on their non-dominant side. This group demonstrated strength impairments in 
both IR and ER that show a 26-28% deficit compared to a population of women without a 
history of breast cancer.  Additionally, the strength values of BC in this study are more than 30% 
less than published reference values for a healthy population of similar aged females.14,31 
Although methodologies for measurement differed slightly (flexion resistance at the epicondyle 
instead of distally at the ulnar styloid process,14 and rotation positioning at 45°14,31 instead of 90° 
abduction which was used in this study), the deficits appear greater than can be explained by 
differing methodologies. It is possible that recovery of strength does not occur spontaneously but 
with use of the upper extremity, and the lack of apparent recovery seen in the BC whose 
involved limb is non-dominant may be due to lower levels of non-dominant limb use in daily 
activities. In studies of arm activity using accelerometry among healthy individuals, the non-
dominant limb typically has less activity than the dominant.38 This loss of strength occurring in 
the involved non-dominant limb was interesting because these strength deficits were not 
observed in the dominant limb, suggesting that women with breast cancer involving their non-
dominant limb may need to be managed differently than women with breast cancer in their 
dominant limb. 
Research on muscular endurance among BC is limited. Two published studies that have 
examined muscular endurance have used the Upper Body Strength and Endurance Test, for 
which psychometric data are unavailable.39,40 Results from these studies show less endurance in 
the involved limb compared to the non-involved limb. The current study is the first study to 
 
examine the use of the FIT-HaNSA in a population of BC. Findings in this study indicate that 
upper extremity endurance is not impaired compared to a similar healthy population. The lack of 
differences found between groups may be due to the level of variance among the two groups. A 
large ceiling effect was observed in performing the FIT-HaNSA; 66-81% of CTRL completed 
the full test duration of 300 seconds and 53-76% of BC completed the full test. Examining 
muscular endurance with a more responsive test without a ceiling effect might provide a clearer 
picture of the level of muscular endurance among BC. 
 When examining the statistically significant deficits in light of clinical relevance in 
DASH scores, ROM, and involved non-dominant limb strength, most daily activities can be 
completed at reported levels, but it is higher level functional activities which may be 
compromised among this group of BC. The DASH outcome measure was designed to evaluate 
an overall level of disability and questions are answered based on an individual’s ability to 
perform a task regardless of limb used.41  This may explain why scores among BC are similar to 
a healthy population as not all tasks would be performed with the involved limb. Additionally, 
this outcome measure only asks one out of 30 questions related to reaching overhead and may 
not be capturing disabilities related to reaching overhead to higher levels. The limitation to 
higher ROM seen in nearly 60% of participants suggest that although most daily tasks can be 
completed, tasks which require greater motion, such as reaching high shelves or participating in 
overhead activities, may be difficult to perform. Certainly, clear deficits in strength are noted 
among women who experienced breast cancer on their non-dominant side, and this strength 
deficit can affect the ability to complete more demanding functional tasks that require higher 




Several limitations in this study may have impacted the results. As the sample was 
limited to women with more involved cancer treatments, these results may not be 
generalizable to the subset of women who were treated with lumpectomy, sentinel node 
biopsy, or chest wall radiation alone. Incomplete data regarding therapy intervention after 
surgical treatment for cancer and before data collection makes analysis of the impact of 
intervention difficult. It is possible that those who had interventions directed toward upper 
extremity functional return may have skewed the results. Incomplete data about how many 
women underwent reconstructive surgery is also a limitation; the impact of reconstructive 
surgery on arm function cannot fully be assessed.  However, with two-thirds of those who 
had a mastectomy reporting on reconstruction status, it appears about half of the sample 
who had mastectomies underwent reconstruction.  In addition, the range of time after breast 
cancer treatment was long (12-336 months) and may have allowed normal tissue healing to 
occur, thus mitigating long-term functional deficits. A longitudinal study would help 
differentiate at what point in time following treatment BC symptoms improve giving insight into 
the probable timeline for return of function. The variance associated with the FIT-HaNSA was 
large (>60 seconds), suggesting the measure was not sensitive enough to identify those 
individuals with decreased endurance. Furthermore, the significant ceiling effect does not allow 
for discrimination between groups. 
Conclusion 
Although long-term BC often report upper extremity functional limitations, the results of 
this study indicate that at an average of four years post-treatment, most women recover ROM 
and strength to levels similar to age-matched women without breast cancer. The important new 
 
finding focuses on which limb was involved with cancer treatment.  Those women whose cancer 
impacted the non-dominant limb appear to demonstrate long-term deficits that their dominant 
involved limb counterparts do not. While the clinical relevance of these statistically significant 
lower ROM and strength values among women with non-dominant involvement may not seem 
important, these women continue to report functional deficits higher than age-matched 
counterparts without shoulder dysfunction. That most daily tasks can be completed with the 
available ROM and strength measured show some recovery of function. However, the findings in 
this study revealing a loss of shoulder flexion motion which can impact certain activities 
requiring a higher reach, and the unexpected finding that strength deficits affecting BC only who 
have experienced cancer in the non-dominant limb, remain a novel and important result that can 
impact clinical care for this subset of women with breast cancer. These findings were the most 
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Table 1.  Participant Demographics, Mean (SD) 





Age, years (range) 57 (41-67) 56 (41-69) 54 (40-68) 
BMI 28.3 (6.4) 27.3 (5.9) 26.8 (5.4) 
IPAQ, mets  2580 (2441) 3071 (4567) 3190 (2926) 
Time since surgery, months 
(range) 51 (12-336)  
Surgery   
Mastectomy alone 8 15  
Mastectomy + ALND  3 2  
Mastectomy + ALND + 
Axillary Radiation 3 3  
ALND + Axillary 
Radiation 4 2  
Previous Rehabilitation 
(n=35) 5 11  
BMI = Body Mass Index; IPAQ = International Physical Activity Questionnaire; ALND = Axillary Lymph Node 
Dissection
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value CI ES 
DASH 12.3 (13.1) 3.3 (4.6) 0.008* 2.20, 16.21 1.13 12.0 (11.6) 3.3 (4.6) ≤0.001* 3.33, 14.36 1.13 
Range of Motion (in degrees except as noted) 
Flexion 140 (17) 154 (9.0) 0.006* -13.08, -.11 1.19 146 (14) 152 (9.0) 0.07 -13.57, .46 0.55 
External 
Rotation 83 (15) 94 (7.0) 0.009* -18.62, -1.98 1.11 90 (12) 95 (9.0) 0.15 -11.02, 1.17 0.50 
HBB (cm) 16.6  (6.3) 13.5 (4.1) 0.092 -1.09, 4.13 0.64 17.6 (5.4) 17.0 (4.5) 0.83 -2.16, 3.50 0.12 
Strength (% of body weight) 
Flexion 7.3 (3.1) 8.7 (3.1) 0.24 -.03, .01 0.45 8.5 (3.0) 9.2 (3.0) 0.06 .73, .97 0.23 
External 
Rotation 10.3 (4.7)* 14.3 (4.4) 0.003* .09, .12 0.89 14.3 (5.4) 14.3 (4.2) 0.27 .12, .16 0.0 
Internal 
Rotation 10.5 (3.5)* 14.2 (4.2) 0.001* .10, .13 0.92 12.7  (4.2) 14.3 (4.5) 0.99 .11, .14 0.36 
Muscular Endurance (in seconds) 
FIT-HaNSA 
2 237.1 (86.7) 262.7 (67.7) 0.42 -63.74, 19.93 0.35 246.0 (77.8) 269.7 (56.8) 0.35 -64.04, 17.33 0.37 
FIT-HaNSA 
3 257.7 (69.4) 281.1 (45.1) 0.31 -61.90, 15.19 0.44 269.9 (67.2) 281.1 (45.1) 0.71 -45.89, 23.49 0.21 
*Significant at alpha ≤0.05 2 
CI = confidence interval; DASH = Disabilities of the Arm, Shoulder, Hand; ES = effect size; FIT-HaNSA = Functional Impairment Test-Hand and Neck, 3 
Shoulder, Arm; HBB = hand behind back 4 
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Figure Legend: 5 
Fig 1a  Flexion ROM 6 
Arc of motion generated for illustrative purposes only by Kinovea.org 7 
Fig 1b  External Rotation ROM 8 
Arc of motion generated for illustrative purposes only by Kinovea.org 9 
Fig 1c  Hand Behind Back Motion 10 
Fig 2a  Flexion Strength 11 
Fig 2b  Internal Rotation Strength 12 
Fig 2c  External Rotation Strength 13 
Fig 3a FIT-HaNSA sub-test 2  14 
Fig 3b  FIT-HaNSA sub-test 3 15 
  16 
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Figure 1b 26 
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Figure 1c 28 
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